Literature DB >> 35676593

Genotypic-Phenotypic Analysis, Metabolic Profiling and Clinical Correlations in Parkinson's Disease Patients from Tamil Nadu Population, India.

Dhivya Venkatesan1, Mahalaxmi Iyer2, Robert Wilson S3, Arul Narayanasamy4, Siva Kamalakannan5, Abilash Valsala Gopalakrishnan6, Balachandar Vellingiri7.   

Abstract

Parkinson's disease (PD) is an ageing disorder caused by dopaminergic neuron depletion with age. Growing research in the field of metabolomics is expected to play a major role in PD diagnosis, prognosis and therapeutic development. In this study, we looked at how SNCA and GBA1 gene mutations, as well as metabolomic abnormalities of kynurenine and cholesterol metabolites, were linked to alpha-synuclein (α-syn) and clinical characteristics in three different PD age groups. In all three age groups, a metabolomics analysis revealed an increased amount of 27-hydroxycholesterol (27-OHC) and a lower level of kynurenic acid (KYNA). The effect of 27-OHC on SNCA and GBA1 modifications was shown to be significant (P < 0.05) only in the A53T variant of the SNCA gene in late-onset and early-onset PD groups, whereas GBA1 variants were not. Based on the findings, we observed that the increase in 27-OHC would have elevated α-syn expression, which triggered the changes in the SNCA gene but not in the GBA1 gene. Missense variations in the SNCA and GBA1 genes were investigated using the sequencing technique. SNCA mutation A53T has been linked to increased PD symptoms, but there is no phenotypic link between GBA1 and PD. As a result of the data, we hypothesise that cholesterol and kynurenine metabolites play an important role in PD, with the metabolite 27-OHC potentially serving as a PD biomarker. These findings will aid in the investigation of pathogenic causes as well as the development of therapeutic and preventative measures for PD.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Alpha-synuclein; Cholesterol; Genetic alterations; Kynurenine; Parkinson’s disease; Phenotypic signs

Mesh:

Substances:

Year:  2022        PMID: 35676593     DOI: 10.1007/s12031-022-02028-4

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   2.866


  55 in total

1.  Low cardiometabolic risk in Parkinson's disease is independent of nutritional status, body composition and fat distribution.

Authors:  Emanuele Cereda; Erica Cassani; Michela Barichella; Angela Spadafranca; Riccardo Caccialanza; Simona Bertoli; Alberto Battezzati; Gianni Pezzoli
Journal:  Clin Nutr       Date:  2012-03-07       Impact factor: 7.324

2.  Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate.

Authors:  J M Brotchie; I J Mitchell; M A Sambrook; A R Crossman
Journal:  Mov Disord       Date:  1991       Impact factor: 10.338

3.  Brain neutral lipids mass is increased in alpha-synuclein gene-ablated mice.

Authors:  Gwendolyn Barceló-Coblijn; Mikhail Y Golovko; Isabella Weinhofer; Johannes Berger; Eric J Murphy
Journal:  J Neurochem       Date:  2007-01-23       Impact factor: 5.372

4.  Metabolomics profiling reveals altered lipid metabolism and identifies a panel of lipid metabolites as biomarkers for Parkinson's disease related anxiety disorder.

Authors:  Mei-Xue Dong; Ling Hu; You-Dong Wei; Guang-Hui Chen
Journal:  Neurosci Lett       Date:  2021-01-10       Impact factor: 3.046

5.  Alternations of Metabolic Profile and Kynurenine Metabolism in the Plasma of Parkinson's Disease.

Authors:  Kuo-Hsuan Chang; Mei-Ling Cheng; Hsiang-Yu Tang; Cheng-Yu Huang; Yih-Ru Wu; Chiung-Mei Chen
Journal:  Mol Neurobiol       Date:  2018-01-02       Impact factor: 5.590

6.  Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein.

Authors:  Nelson B Cole; Diane D Murphy; Theresa Grider; Susan Rueter; Dawn Brasaemle; Robert L Nussbaum
Journal:  J Biol Chem       Date:  2001-12-14       Impact factor: 5.157

7.  Lipid metabolic dysregulation is involved in Parkinson's disease dementia.

Authors:  Mei-Xue Dong; You-Dong Wei; Ling Hu
Journal:  Metab Brain Dis       Date:  2021-01-12       Impact factor: 3.584

8.  Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex.

Authors:  M F Beal; W R Matson; E Storey; P Milbury; E A Ryan; T Ogawa; E D Bird
Journal:  J Neurol Sci       Date:  1992-03       Impact factor: 3.181

9.  Survival and dementia in GBA-associated Parkinson's disease: The mutation matters.

Authors:  Roberto Cilia; Sara Tunesi; Giorgio Marotta; Emanuele Cereda; Chiara Siri; Silvana Tesei; Anna L Zecchinelli; Margherita Canesi; Claudio B Mariani; Nicoletta Meucci; Giorgio Sacilotto; Michela Zini; Michela Barichella; Corrado Magnani; Stefano Duga; Rosanna Asselta; Giulia Soldà; Agostino Seresini; Manuela Seia; Gianni Pezzoli; Stefano Goldwurm
Journal:  Ann Neurol       Date:  2016-10-03       Impact factor: 10.422

Review 10.  Mitochondrial dysfunction: A hidden trigger of autism?

Authors:  Vellingiri Balachandar; Kamarajan Rajagopalan; Kaavya Jayaramayya; Madesh Jeevanandam; Mahalaxmi Iyer
Journal:  Genes Dis       Date:  2020-07-16
View more
  1 in total

Review 1.  Influence of heavy metals in Parkinson's disease: an overview.

Authors:  Balachandar Vellingiri; Atchaya Suriyanarayanan; Kripa Susan Abraham; Dhivya Venkatesan; Mahalaxmi Iyer; Neethu Raj; Abilash Valsala Gopalakrishnan
Journal:  J Neurol       Date:  2022-07-28       Impact factor: 6.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.